Investigations into the emergence of pertactin-deficient bordetella pertussis isolates in six European countries, 1996 to 2012

A. Zeddeman*, M. van Gent, C. J. Heuvelman, H. G. van der Heide, M. J. Bart, A. Advani, H. O. Hallander, C. H. Wirsing von König, M. Riffelman, J. Storsaeter, D. F. Vestrheim, T. Dalby, K. A. Krogfelt, N. K. Fry, A. M. Barkoff, J. Mertsola, Q. He, F. Mooi

*Corresponding author

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


Pathogen adaptation has been proposed to contribute to the resurgence of pertussis. A striking recent example is the emergence of isolates deficient in the vaccine component pertactin (Prn). This study explores the emergence of such Prn-deficient isolates in six European countries. During 2007 to 2009, 0/83 isolates from the Netherlands, 0/18 from the United Kingdom, 0/17 Finland, 0/23 Denmark, 4/99 Sweden and 5/20 from Norway of the isolates collected were Prn-deficient. In the Netherlands and Sweden, respectively 4/146 and 1/8 were observed in a later period (2010–12). The Prn-deficient isolates were genetically diverse and different mutations were found to inactivate the prn gene. These are indications that Prn-deficiency is subject to positive selective pressure. We hypothesise that the switch from whole cell to acellular pertussis vaccines has affected the balance between ‘costs and benefits’ of Prn production by Bordetella pertussis to the extent that isolates that do not produce Prn are able to expand. The absence of Prn-deficient isolates in some countries may point to ways to prevent or delay the spread of Prn-deficient strains. In order to substantiate this hypothesis, trends in the European B. pertussis population should be monitored continuously.

Udgave nummer33
Antal sider11
StatusUdgivet - 21 aug. 2014
Udgivet eksterntJa

Citer dette